Resources

533 Resources for

healthcare and sec

Subscribe to this listing via:
RSS
Email

BNET Resources

PhytoMedical's In Vivo Toxicity and Efficacy Tests on Human Colon Cancer Deliver Promising Results: Anti-cancer compound exhibits significant efficacy and toxicity values leading to further development PRINCETON, N.J. -- PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced the results of its anti-cancer compound in vivo toxicity and efficacy tests on HCT116 human colon cancer cells was successful. "I am encouraged by the...; Tags: Company, efficacy, FINANCE, HEALTHCARE, Investment, SEC; Research articles 2008-10-27
RegeneRx Sponsors "Walk a Mile in My Shoes" for National Epidermolysis Bullosa Awareness Week: BETHESDA, Md. -- REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it is a major sponsor of "Walk a Mile in My Shoes," the signature event of National Epidermolysis Bullosa EB Awareness Week. The "Walk a Mile in My Shoes" program coordinates events that include rallies, meetings and walk-a-thons in...; Tags: Company, efficacy, HEALTHCARE, RegeneRX Biopharmaceuticals Inc., SEC, wound; Research articles 2008-10-24
RegeneRx President and CEO to Speak at 7th Annual BIO Investor Forum: BETHESDA, Md. -- REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) announced today that J.J. Finkelstein, RegeneRx's president and chief executive officer, will present a company update at the 7th Annual BIO Investor Forum in San Francisco, CA, on Thursday, October 30, 2008 at 2:00 p.m. ET. To listen and view the presentation investors...; Tags: Company, efficacy, HEALTHCARE, RegeneRX Biopharmaceuticals Inc., SEC; Research articles 2008-10-22
Velcera Announces Voluntary Termination of Registration With the SEC: Velcera, Inc. (OTCBB: VLCR), a specialty pharmaceutical company focused on pet health, announced today that it has filed a Form 15 with the Securities and Exchange Commission ("SEC"). As a result, effective immediately, the Company's obligation to file reports with the SEC has terminated. The SEC has 90 days...; Tags: Benefits, Company, HEALTHCARE, SEC, SOFTWARE, termination; Research articles 2008-10-17
QuadraMed Corporation Repurchases 620,614 Common Shares from Single Holder: RESTON, Va. -- QuadraMed Corporation (NASDAQ:QDHC) announced today that it has entered into an agreement to purchase 620,614 of its common shares from a single shareholder, at $5.50 per share, for a total purchase price of approximately $3.4 million. The Company will use its available cash to pay the purchase...; Tags: Benefits, FINANCE, financial, HEALTHCARE, Investment, QuadraMed Corp., SEC, SOFTWARE, stock; Research articles 2008-10-16

Omrix Biopharmaceuticals Receives Approval from European Medicines Agency for Evicel Liquid Fibrin Sealant: NEW YORK -- OMRIX Biopharmaceuticals, Inc. ("Omrix" or the "Company") (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today that it has received approval from the European Medicines Agency EMEA for Evicel, the Company's liquid fibrin sealant. The EMEA's approval permits EVICEL...; Tags: agency, Benefits, Company, EMEA, HEALTHCARE, MARKETING, PRODUCTIVITY, SEC, SOFTWARE, surgery; Research articles 2008-10-14
Omrix Biopharmaceuticals Provides Update On Fibrin Pad U.S. Phase II Clinical Trial In Mild to Moderate Bleeding: NEW YORK -- Omrix Biopharmaceuticals, Inc. ("Omrix") (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today that the Fibrin Pad U.S. Phase II clinical trial in mild to moderate bleeding was suspended yesterday afternoon to investigate an incident of post-operative bleeding. The Company...; Tags: Company, HEALTHCARE, SEC; Research articles 2008-10-09
PhytoMedical Renews Sponsored Research Agreement with Dartmouth College: Anti-cancer compound development results of the past year strengthen working relationship PRINCETON, N.J. -- PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced that it is renewing its Sponsored Research Agreement with Dartmouth College. "I am extremely pleased to have extended our agreement with Dartmouth College," stated Mr. Greg...; Tags: agreement, Company, Dartmouth College, FINANCE, HEALTHCARE, Investment, SEC, U.S.; Research articles 2008-10-06
HepaLife Announces Expansion of Exclusive License Agreement with U.S. Government Agency for Liver Cell Line: HepaLife's expanded agreement with US Department of Agriculture allows for use of patented PICM-19 liver stem cell line as a malaria infection host system, in addition to artificial liver devices and in-vitro toxicological testing platforms. BOSTON -- HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (WKN: 500625) today announced that...; Tags: agency, agreement, Cell, Company, HEALTHCARE, malaria, SEC, stem-cell, U.S. Department of Agriculture, U.S. Government; Research articles 2008-10-01
RegeneRx to Develop RGN-457 for Cystic Fibrosis: RegeneRx Seeking Strategic Partnership to Address CF in U.S. and Europe BETHESDA, Md. -- REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it is seeking a strategic partner to assist in the development of RGN-457 for the treatment of cystic fibrosis CF. RGN-457 is based on thymosin beta 4...; Tags: Company, efficacy, HEALTHCARE, patient, RegeneRX Biopharmaceuticals Inc., SEC, U.S.; Research articles 2008-10-01
Healthaxis Expands Relationship with HealthSCOPE Benefits, Inc: Signs Multi-Year IT Outsourcing Contract to Deliver Additional Outsourcing Solutions Through BPO Management Services, Inc. IRVING, Texas -- Healthaxis, Inc., "Healthaxis" (Nasdaq: HAXS) an innovative provider of technology-enhanced, integrated business process solutions and services, including claims and benefit administration applications, web-enabled software solutions and outsourced claims related services for...; Tags: Benefits, BPO, FINANCE, HARDWARE, HEALTHCARE, Investment, merger, outsource, Outsourcing, SEC, SOFTWARE, Storage; Research articles 2008-09-30
SurModics Acquires CodeLink Activated Slide Business: EDEN PRAIRIE, Minn. -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today the acquisition of the CodeLink[TM] Activated Slide microarray business from GE Healthcare. Terms of the transaction were not disclosed. "Our acquisition of the CodeLink Activated...; Tags: acquisition, Benefits, FINANCE, General Electric Co., HEALTHCARE, Investment, SEC, SOFTWARE; Research articles 2008-09-30
RegeneRx Enrolls First Subject in RGN-352 Phase IB Clinical Trial: BETHESDA, Md. -- REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it has enrolled the first subject in its Phase IB clinical trial in which RGN-352 is being tested in 40 healthy subjects. RGN-352 is an injectable formulation of T4 being developed to reduce cardiac damage in patients after an...; Tags: Company, HEALTHCARE, patient, SEC; Research articles 2008-09-22
Shionogi and Sciele Announce Receipt of United States Antitrust Clearance: OSAKA, Japan & ATLANTA -- Shionogi & Co., Ltd. ("Shionogi") and Sciele Pharma, Inc. ("Sciele") (NASDAQ: SCRX) announced today that the waiting period under the Hart Scott Rodino Antitrust Improvements Act of 1976 with respect to Shionogi's indirect wholly owned subsidiary's cash tender offer for all outstanding shares of common...; Tags: Benefits, Company, HEALTHCARE, SEC, SOFTWARE, TENDER, women; Research articles 2008-09-19
Celera Corporation Files Its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission: ALAMEDA, Calif. -- Celera Corporation (NASDAQ:CRA) today filed its annual report on Form 10-K with the U.S. Securities and Exchange Commission. The annual report on Form 10-K can be accessed through Celera's website at http://www.celera.com and hard copies are available free-of-charge from the Company. About Celera Celera is...; Tags: Benefits, HEALTHCARE, INTERNET, SEC, SOFTWARE; Research articles 2008-09-08
RegeneRx Completes Patient Enrollment of First Phase II Clinical Trial: BETHESDA, Md. -- REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it completed enrollment of its first of four ongoing Phase II clinical trials. The trial is a double-blind, placebo-controlled, dose-escalating clinical trial evaluating the safety and efficacy of the Company's topical drug candidate, RGN-137, in seventy-two patients with pressure...; Tags: Company, efficacy, HEALTHCARE, patient, SEC; Research articles 2008-08-20
Inspire Announces Peer-Reviewed Publications Related to Denufosol for Cystic Fibrosis: DURHAM, N.C. -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today publication of two papers related to the denufosol for cystic fibrosis development program in peer-reviewed journals. The first paper, "Denufosol: A Review of Studies with Inhaled P2Y2 Agonists that led to Phase 3" (D. Kellerman, A. Rossi Mospan, J....; Tags: Government, HEALTHCARE, Inspire Pharmaceuticals Inc., Litigation, SEC; Research articles 2008-08-06
Pluristem Therapeutics Announces $1.6 Million Securities Offering: NEW YORK -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized allogeneic cell therapy products for a variety of degenerative, ischemic and autoimmune indications, today announced it has entered into definitive agreements to sell common stock and warrants to selected institutional investors for aggregate...; Tags: Company, HEALTHCARE, SEC; Research articles 2008-08-06
Lev Reports Second Quarter 2008 Financial Results: NEW YORK -- Lev Pharmaceuticals, Inc. ("Lev") (OTCBB: LEVP) today announced financial results for the three and six months ended June 30, 2008. Highlights and Current Developments: * Lev entered into a plan of merger with ViroPharma on July 15, 2008 for a potential net aggregate value of...; Tags: compensation, FDA, FINANCE, Government, HEALTHCARE, Investment, merger, SEC, stock; Research articles 2008-08-01
QuadraMed to Announce Q2 2008 Results on August 8, 2008: RESTON, Va. -- QuadraMed([R]) Corporation (Amex:QD) announced today that it expects to release its second quarter 2008 financial results on Friday, August 8, 2008. Management will review these results in an investment community conference call on Friday, August 8, 2008 at 5:00 PM Eastern (2:00 PM Pacific). To ensure fair...; Tags: Benefits, HEALTHCARE, SEC, SOFTWARE, Webcast; Research articles 2008-08-01